Antibiotic therapy in serious infectious states;Antibiothérapie des états infectieux graves

Medecine et Maladies Infectieuses

Volumn 36, Issue 6, 2006, Pages 299-303

  Carlet, J ^a   Tabah, A ^a  

^a SAINT JOSEPH HOSPITAL   (France)

Author keywords

Antibiotic therapy; Pharmacodynamics; Pharmacokinetics; Resistance to antibiotics; Severe sepsis

Indexed keywords

AMIKACIN; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CEFEPIME; CEFTAZIDIME; CEPHALOSPORIN; CIPROFLOXACIN; IMIPENEM; LINEZOLID; MACROLIDE; METICILLIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIUM ISOLATE; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG EFFECT; HUMAN; MONOTHERAPY; SEPSIS; SHORT SURVEY; DRUG ADMINISTRATION; INFECTION; REVIEW;

ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; DRUG ADMINISTRATION SCHEDULE; HUMANS; INFECTION;

EID: 33746218189     PISSN: 0399077X     EISSN: 17696690     Source Type: Journal    
DOI: 10.1016/j.medmal.2006.02.002     Document Type: Short Survey

References (41)

1. Alberti C., Brun-Buisson C., Burchardi H., et al. Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study. Intensive Care Med. 28 (2002) 525-526
2. Brun-Buisson C., Meshaka P., Pinton P., et al. Episepsis: a reappraisal of the epidemiology and outcome of severe sepsis in French care units. Intensive Care Med. 30 (2004) 580-588
3. Garnacho-Montero J., Garcia-Garmendia J.L., Barrero-Almodovar A., et al. Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit. Care Med. 12 (2003) 2742-2751
4. Dellinger R.P., Carlet J., Masur H., et al. Surviving Campaign guidelines for management of severe sepsis and septic shock. Crit. Care Med. 32 (2004) 858-873
5. Bochud P.Y., Bonten M., Marchetti O., and Calandra T. Antimicrobial therapy for patients with severe sepsis and septic shock: an evidence-based review. Crit. Care Med. 32 (2004) S495-S512
6. Rello J., Vidaur L., Sandiumenge A., et al. De-escalation therapy in ventilator-associated pneumonia. Crit. Care Med. 32 (2004) 2183-2190
7. Behrendt G., Schneider S., Brodt H.R., et al. Influence of antimicrobial treatment on mortality in septicemia. J. Chemother. 11 (1999) 179-186
8. Ramphal R. Importance of adequate initial antimicrobial therapy. Chemotherapy 51 (2005) 171-176
9. Montravers P., Chalfine A., Gauzit R., et al. Clinical and therapeutic features of nonpostoperative nosocomial intra-abdominal infections. Ann. Surg. 239 (2004) 409-416
10. Craven D.E., Palladino R., and McQuillen D.P. Healthcare-associated pneumonia in adults : management principles to improve outcomes. Infect. Dis. Clin. North Am. 18 (2004) 939-962
11. Trouillet J.L., Chastre J., Vuagnat A., et al. Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am. J. Respir. Crit. Care Med. 157 (1998) 531-539
12. Gonzales R., Bartlett J.G., Besser R.E., et al. Principles of appropriate antibiotic use for treatment of acute respiratory tract infections in adults: background, specific aims, and methods. Ann. Intern. Med. 20 (2001) 479-486
13. Carlet J., Ben Ali A., and Chalfine A. Epidemiology and control of antibiotic resistance in the intensive care unit. Curr. Opin. Infect. Dis. 17 (2004) 309-316
14. Paul M., Benuri-Silbiger I., Soares-Weiser K., et al. Beta lactam monotherapy versis beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials. BMJ 328 (2004) 668
15. Safdar N., Handlsman J., and Maki D.G. Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis. Lancet Infect. Dis. 5 (2005) 129-133
16. Paul M., and Leibovici L. Combination antibiotic therapy for Pseudomonas aeruginosa bacteraemia. Lancet Infect. Dis. 5 (2005) 192-193
17. Paul M., and Leibovici L. Systematic reviews and meta-analysis of febrile neutropenia. Mayo Clin. Proc. 80 (2005) 1122-1125
18. Bliziotis I.A., Samonis G., Vardakas K.Z., et al. Effect of aminoglycoside and beta-lactam combination therapy vs beta-lactam monotherapy on the emergence of antimicrobial resistance: a meta-analysis of randomized, controlled trials. Clin. Infect. Dis. 41 (2005) 149-158
19. Baddour L.M., Yu V.L., Klugman K.P., et al. Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am. J. Respir. Crit. Care Med. 170 (2004) 440-444
20. Saleh-Mghir A., Ameur N., Muller-Serieys C., et al. Combination of quinupristin-dalfopristin (Synercid) and rifampin is highly synergistic in experimental Staphylococcus aureus joint prosthesis infection. Antimicrob. Agents Chemother. 46 (2002) 1122-1124
21. Schaad H.J., Chuard C., Vaudaux P., et al. Teicoplanin alone or combined with rifampin compared with vancomycin for prophylaxis and treatment of experimental foreign body infection by methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 38 (1994) 1703-1710
22. Henry N.K., Rouse M.S., Whitesell A.L., et al. Treatment of methicillin-resistant Staphylococcus aureus experimental osteomyelitis with ciprofloxacin or vancomycin alone or in combination with rifampin. Am. J. Med. 82 (1987) 73-75
23. Jacqueline C., Navas D., Batard E., et al. In vitro and in vivo synergistic activities of linezolid combined with subinhibitory concentrations of imipenem against methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 49 (2005) 45-51
24. Boselli E., Breilh D., Rimmerle T., et al. Pharmacokinetics and intrapulmonary diffusion of levofloxacin in critically ill patients with severe community-acquired pneumonia. Crit. Care Med. 33 (2005) 104-109
25. Arslan H., Azap O.K., Ergonul O., et al. Risk factors for ciprofloxacin resistance among Escherichia coli strains isolated from community-acquired urinary tract infections in Turkey. J. Antimicrob Chemother 56 (2005) 914-918
26. De Paepe P., Belpaire F.M., and Buylaert W.A. Pharmacokinetic and pharmacodynamic considerations when treating patients with sepsis and septic shock. Clin. Pharmacokinet. 41 (2002) 1135-1151
27. Spanu T., Santangelo R., Andreotti F., et al. Antibiotic therapy for severe bacterial infections : correlation between the inhibitory quotient and outcome. Int. J. Antimicrob. Agents 23 (2004) 120-128
28. Joukhadar C., Klein N., Mayer B.X., et al. Plasma and tissue pharmacokinetics of cefpirome in patients with sepsis. Crit. Care Med. 30 (2002) 1478-1482
29. Joukhadar C., Frossard M., Mayer B.X., et al. Impaired target site penetration of beta-lactams may account for therapeutic failure in patients with septic shock. Crit. Care Med. 29 (2001) 385-391
30. Mehrotra R., De Gaudio R., and Palazzo M. Antibiotic pharmacokinetic and pharmacodynamic considerations in critical illness. Intensive Care Med. 30 (2004) 2145-2156
31. Buijk S.E., Mouton J.W., Gyssens I.C., et al. Experience with a once-daily dosing program of aminoglycosides in critically ill patients. Intensive Care Med. 28 (2002) 936-942
32. Jacqueline C., Batard E., Perez L., et al. In vitro efficacy of continuous infusion versus intermittent dosing of linezolid compared to vancomycin in a methicillin-resistant Staphylococcus aureus rabbit endocarditis model. Antimicrob. Agents Chemother. (2002) 46
33. Wysocki M., Delatour F., Faurisson F., et al. Continuous vs intermittent infusion of vancomycin in severe Staphylococcal infections: prospective multicenter randomized study. Antimicrob. Agents Chemother. 45 (2001) 2460-2467
34. Kasiakou S.K., Sermaides G.J., Michalopoulos A., et al. Continuous versus intermittent intravenous administration of antibiotics: a meta-analysis of randomised controlled trials. Lancet Infect. Dis. 5 (2005) 581-589
35. Rello J. Pharmacokinetics, pharmacodynamics, safety and tolerability of tigecycline. J. Chemother. 17 (2005) 12-22
36. Goldstein I., Wallet F., Nicolas-Robin A., et al. Lung deposition and efficiency of nebulized amikacin during Escherichia coli pneumonia in ventilated piglets. Am. J. Respir. Crit. Care Med. 166 (2002) 1375-1381
37. Archer G.L., Johnston J.L., Vazquez G.J., et al. Efficacy of antibiotic combinations including rifampin against methicillin-resistant Staphylococcus epidermidis: in vitro and in vivo studies. Rev. Infect. Dis. 5 (1983) S538-S542
38. Tsuji M., Matsuda H., Miwa H., et al. Antimicrobial-induced release of endotoxin from Pseudomonas aeruginosa: comparison of in vitro and animal models. J. Antimicrob. Chemother. 51 (2003) 353-359
39. Van de Beek D., De Gans J., McIntyre P., et al. Steroids in adults with acute bacterial meningitis : a systematic review. Lancet Infect. Dis. 4 (2004) 139-143
40. Chastre J., Wolff M., Fagon J.Y., et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 19 (2003) 2588-2598
41. Luyt C.E., Guerin V., Combes A., et al. Procalcitonin kinetics as a prognostic marker of ventilator-associated pneumonia. Am. J. Respir. Crit. Care Med. 171 (2005) 48-53